Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

A new study has shown that two drugs - lecanemab and donanemab - could help patients stay independently by approximately 10–13 months in the early stage of Alzheimer's disease.

The "Seizures Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The Seizures treatment pipeline analysis provides an overview of recent advancements ...

Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

Trump's trade threats and tariffs target various countries and industries, sparking fears of a global trade war.

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Total Revenues of $491.7 Million, Marking Another Year of Record GrowthFull Year 2024 Total Revenues Grew 23.5% YoY, Driven by ...

Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted. The attack has affected servers both ...

Allarity expects to pursue multiple advantaged regulatory pathways to expedite approval in the first half of 2025. Allarity ...